Adeptus Biotechnologies Corp. (ADPT) PT Raised to $21 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $26.53 +2.83%
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Guggenheim analyst Subbu Nambi raised the price target on Adeptus Biotechnologies Corp. (NASDAQ: ADPT) to $21.00 (from $20.00) while maintaining a Buy rating.
You May Also Be Interested In
- Insulet Corporation (PODD) PT Raised to $163 at TD Cowen
- Livanova (LIVN) PT Raised to $115 at Mizuho
- Livanova (LIVN) PT Raised to $120 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
